Anteris Technologies Global Corp. develops structural heart medical devices for aortic valve disease, with its lead product, the DurAVR® Transcatheter Heart Valve, designed for patients with aortic stenosis. News about AVR commonly centers on the DurAVR THV System, the ADAPT® anti-calcification tissue technology, the ComASUR® Delivery System and the company’s work in transcatheter aortic valve replacement.
Company updates also cover the PARADIGM global pivotal trial, including clinical enrollment, U.S. reimbursement under Medicare coverage for TAVR procedures, regulatory and clinical strategy, manufacturing expansion, capital raises, strategic investment activity, financial results and healthcare investor conference presentations. The company is listed on Nasdaq and ASX under the symbol AVR.
Anteris Technologies (NASDAQ/ASX: AVR), a structural heart company developing the DurAVR THV biomimetic heart valve, has announced its participation in two major healthcare investor conferences.
CEO Wayne Paterson will present at both the 45th Annual TD Cowen Healthcare Conference and the Barclays 27th Annual Global Healthcare Conference. Additionally, Chief Medical Officer Dr. Chris Meduri will participate as an expert panelist in the Structural Heart-TAVR panel discussion, which will be moderated by Joshua Jennings.
Investors can access the conference fireside chat webcasts through the Investor Center section on the Anteris website, where recordings will remain available for up to 90 days.
Anteris Technologies Global Corp. (AVR) has completed its U.S. initial public offering, raising $88.8 million through the sale of 14.8 million shares at $6.00 per share. The company began trading on NASDAQ on December 13, 2024, under ticker 'AVR'. An additional $13.3 million could be raised if underwriters exercise their Green Shoe option for 2.22 million shares.
The company plans to list its CHESS Depositary Interests on ASX on December 17, 2024. Proceeds will primarily fund the development of DurAVR® transcatheter heart valve and a global pivotal study for treating severe aortic stenosis, with remaining funds allocated to working capital and debt repayment.
Anteris Technologies Global Corp. (AVR) has announced the pricing of its U.S. Initial Public Offering of 14,800,000 shares at $6.00 per share. Trading is expected to begin on the Nasdaq Global Market on December 13, 2024, under the ticker symbol 'AVR', with the offering closing on December 16, 2024.
The underwriters have a 30-day option to purchase up to an additional 2,220,000 shares. The company plans to use the proceeds for the development of its DurAVR® transcatheter heart valve, preparation for a global pivotal study, working capital, and debt repayment. TD Cowen, Barclays, and Cantor are joint book-running managers, with Lake Street Capital Markets as lead manager.